Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data
Devon Conway1, Jessica Cooperrider1, Jeffrey Lambe1, Mengke Du1, Michelle Chu2, Michael Gatza3, Corey Cusack3, Jacqueline Takere Abam3, Jennifer Reardon3, Burhan Chaudhry3, Christina Schroedle4, Carrie Hersh5
1Cleveland Clinic, 2Oregon Health and Science University, 3BMS, 4Marian University, 5Cleveland Clinic Lou Ruvo Center for Brain Health
Objective:

To determine safety and effectiveness of ozanimod in a real-world cohort of people with multiple sclerosis (PwMS) with up to two years of follow-up.

Background:
Ozanimod is approved for treatment of relapsing MS with safety and efficacy established in clinical trials. Real-world data outside of the closely regulated trial environment is needed to inform ozanimod use in a broader population.
Design/Methods:

Data were collected for PwMS receiving ozanimod at our MS centers, including baseline data from the year prior. PwMS or clinically isolated syndrome, ≥1 dose of ozanimod, and age ≥18 years at ozanimod initiation were included. Demographic, disease history, relapse, side effect, imaging, infection, and performance test data were collected.

Results:

The cohort included 205 PwMS with an average age of 47.2 years and average disease duration of 12.5 years. There were 51 (25%), 60 (29%), and 17 (8.3%) individuals with hypertension, hyperlipidemia, and type 2 diabetes, respectively. Two-year data were available for 92 PwMS in the cohort. The annualized relapse rate for the entire cohort was 0.03, an incident rate ratio of 0.3 compared to baseline (p<0.001). There were 48 MRIs obtained at 24 months and 3 (6.3%) showed a new or enlarging T2 lesion (odds ratio compared to baseline=0.10, p<0.001) while none showed a gadolinium-enhancing lesion. There were no significant differences in performance tests relative to baseline. Tolerability concerns were reported by 16% of the cohort at 2 years, with headache being most common. Upper respiratory infections were most common, cumulatively affecting 40% of the cohort over 2 years. Ozanimod was discontinued in 59 (28.8%) individuals by 2 years after a mean duration of 247.9 days.

Conclusions:

This real-world ozanimod-treated cohort included individuals who were older, had longer disease duration, and had more comorbidities than in the clinical trials. Ozanimod was effective with no new safety or tolerability signals.

10.1212/WNL.0000000000213291
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.